Compare Noble Corporation plc (NE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs State Street SPDR S&P Biotech ETF — how do they compare? Noble Corporation plc trades at $44.21 (market cap $7.10B), while State Street SPDR S&P Biotech ETF trades at $158.83. The key difference: Noble Corporation plc pays a 4.5% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Noble Corporation plc nearer its low. Which is the better fit depends on your goals.
| NE | XBI | |
|---|---|---|
Market Cap | $7.10B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $54.37 | $164.28 |
52-Week Low | $26.61 | $86.92 |
Enterprise Value | $8.53B | — |
Dividend Yield | 4.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $44.48, up 2.14% today, with a bullish technical signal driven by moving averages. The stock shows mixed earnings performance, with a Q1 2026 beat but a Q2 2026 miss, while revenue and net income have declined year-over-year. Recent news highlights multiple law firm investigations into the company, adding uncertainty. The consensus price target is $46.00, slightly above the current price, with analysts divided between Buy (31%) and Hold (43%) ratings.
The outlook is cautious due to earnings volatility and legal scrutiny, though positive cash flow and a solid backlog of $6.8 billion provide some stability. Key risks include operational suspensions and investor litigation, while potential upside hinges on execution improvements and contract wins. The stock's valuation appears stretched with a P/E of 47.32, demanding strong future growth to justify current levels.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
